Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer

Basit Öğe Kaydı
dc.authoridYavuzsen, Tugba/0000-0001-9375-8133
dc.authoridkahraman, seda/0000-0002-5328-6554
dc.authoridErul, Enes/0000-0002-2487-2087
dc.authoridSahin, Elif/0000-0002-1976-3951
dc.authoridDulgar, Ozgecan/0000-0002-0678-4024
dc.authoridhacibekiroglu, ilhan/0000-0002-0333-7405
dc.authoridAydin, Esra/0000-0003-0210-3153
dc.contributor.authorKahraman, Seda
dc.contributor.authorErul, Enes
dc.contributor.authorSeyyar, Mustafa
dc.contributor.authorGumusay, Ozge
dc.contributor.authorBayram, Ertugrul
dc.contributor.authorDemirel, Burcin Cakan
dc.contributor.authorAcar, Omer
dc.date.accessioned2024-10-29T17:59:01Z
dc.date.available2024-10-29T17:59:01Z
dc.date.issued2023
dc.departmentTekirdağ Namık Kemal Üniversitesi
dc.description.abstractBackground: Ribociclib, palbociclib and abemaciclib are currently approved CDK4/6 inhibitors along with aromatase inhibitors as the first-line standard-of-care for patients with hormone receptor-positive, HER2-negative metastatic breast cancer. Methods: The authors report retrospective real-life data for 600 patients with estrogen receptor- and/or progesterone receptor-positive and HER2-negative metastatic breast cancer who were treated with ribociclib and palbociclib in combination with letrozole. Results & conclusion: The results demonstrated that the combination of palbociclib or ribociclib with letrozole has similar progression-free survival and overall survival benefit in real life for the patient group with similar clinical features. Specifically, endocrine sensitivity may be a factor to be considered in the treatment preference.
dc.identifier.doi10.2217/fon-2022-1287
dc.identifier.issn1479-6694
dc.identifier.issn1744-8301
dc.identifier.pmid37133230
dc.identifier.scopus2-s2.0-85159731947
dc.identifier.scopusqualityQ1
dc.identifier.urihttps://doi.org/10.2217/fon-2022-1287
dc.identifier.urihttps://hdl.handle.net/20.500.11776/14594
dc.identifier.wosWOS:000991646700001
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherFuture Medicine Ltd
dc.relation.ispartofFuture Oncology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectCDK 4
dc.subject6 inhibitors
dc.subjectHER2-negative metastatic breast cancer
dc.subjectHR-positive
dc.subjectletrozole
dc.titleTreatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu